Key points are not available for this paper at this time.
The RATIONALE-307 final analysis demonstrated superior clinical benefit with addition of tislelizumab to chemotherapy, and a manageable safety profile, as first-line treatment of advanced sq-NSCLC.
Wang et al. (Wed,) studied this question.